{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:30:36Z","timestamp":1789165836624,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ajo.2019.10.012","type":"journal-article","created":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T18:41:06Z","timestamp":1571683266000},"page":"86-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Noncompliance in Prospective Retina Clinical Trials: Analysis of Factors Predicting Loss to Follow-up"],"prefix":"10.1016","volume":"210","author":[{"given":"Brenda","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis C.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Rusakevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2019.10.012_bib1","series-title":"BIO Industry Analysis","article-title":"Clinical development success rates 2006-2015","author":"Thomas","year":"2016"},{"issue":"11","key":"10.1016\/j.ajo.2019.10.012_bib2","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1001\/jamainternmed.2018.3931","article-title":"Estimated costs of pivotal trials for novel therapeutic agents approved by the us food and drug administration, 2015-2016","volume":"178","author":"Moore","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1016\/j.ajo.2019.10.012_bib3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2147\/OPTH.S2561","article-title":"Potential bias in ophthalmic pharmaceutical clinical trials","volume":"2","author":"Varner","year":"2008","journal-title":"Clin Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2019.10.012_bib4","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/jcph.689","article-title":"Mitigating the effects of nonadherence in clinical trials","volume":"56","author":"Shiovitz","year":"2016","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.ajo.2019.10.012_bib5","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/psp4.12361","article-title":"A systematic evaluation of effect of adherence patterns on the sample size and power of a clinical study","volume":"7","author":"Mallayasamy","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"10.1016\/j.ajo.2019.10.012_bib6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1124\/mi.11.2.8","article-title":"The secrets of a successful clinical trial: compliance, compliance, and compliance","volume":"11","author":"Czobor","year":"2011","journal-title":"Mol Interv"},{"issue":"10","key":"10.1016\/j.ajo.2019.10.012_bib7","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1001\/jamaophthalmol.2018.3255","article-title":"Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial","volume":"136","author":"Gross","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2019.10.012_bib8","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1167\/iovs.15-16444","article-title":"Barriers to follow-up and strategies to improve adherence to appointments for care of chronic eye diseases","volume":"56","author":"Thompson","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"10.1016\/j.ajo.2019.10.012_bib9","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2018.02.034","article-title":"Loss to follow-up in patients with proliferative diabetic retinopathy after panretinal photocoagulation or intravitreal anti-VEGF injections","volume":"125","author":"Obeid","year":"2018","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2019.10.012_bib10","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.oret.2018.11.002","article-title":"Loss to follow-up after intravitreal anti\u2013vascular endothelial growth factor injections in patients with diabetic macular edema","volume":"3","author":"Gao","year":"2019","journal-title":"Ophthalmol Retina"},{"issue":"11","key":"10.1016\/j.ajo.2019.10.012_bib11","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jamaophthalmol.2018.3578","article-title":"Loss to follow-up among patients with neovascular age-related macular degeneration who received intravitreal anti\u2013vascular endothelial growth factor injections","volume":"136","author":"Obeid","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2019.10.012_bib12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3928\/23258160-20190301-05","article-title":"Loss to follow-up in patients with retinal vein occlusion undergoing intravitreal anti-VEGF injections","volume":"50","author":"Gao","year":"2019","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"9","key":"10.1016\/j.ajo.2019.10.012_bib13","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.ophtha.2013.06.030","article-title":"Two year SAVE outcomes: 2.0\u00a0mg ranibizumab for recalcitrant neovascular AMD","volume":"120","author":"Wykoff","year":"2013","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajo.2019.10.012_bib14","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ophtha.2017.11.026","article-title":"Targeted retinal photocoagulation for diabetic macular edema with peripheral retinal nonperfusion: three-year randomized DAVE trial","volume":"125","author":"Brown","year":"2018","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2019.10.012_bib15","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.ophtha.2017.01.049","article-title":"Peripheral laser for recalcitrant macular edema owing to retinal vein occlusion: the WAVE trial","volume":"124","author":"Wykoff","year":"2017","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ajo.2019.10.012_bib16","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1097\/IAE.0000000000000191","article-title":"Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial","volume":"34","author":"Brown","year":"2014","journal-title":"Retina"},{"issue":"7","key":"10.1016\/j.ajo.2019.10.012_bib17","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/bjophthalmol-2013-304736","article-title":"Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial)","volume":"98","author":"Wykoff","year":"2014","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2019.10.012_bib18","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/bjophthalmol-2017-310941","article-title":"Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study","volume":"102","author":"Wykoff","year":"2018","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2019.10.012_bib19","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1136\/bjophthalmol-2017-310822","article-title":"Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial","volume":"102","author":"Wykoff","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2019.10.012_bib20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ajo.2019.02.005","article-title":"Randomized trial of treat & extend ranibizumab with & without navigated laser versus monthly dosing for DME: TREX-DME 2 year outcomes","volume":"202","author":"Payne","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2019.10.012_bib21","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.oret.2018.03.008","article-title":"Suprachoroidal triamcinolone acetonide for diabetic macular edema: the HULK trial","volume":"2","author":"Wykoff","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ajo.2019.10.012_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.oret.2019.07.011","article-title":"Intravitreal aflibercept for retinal non-perfusion in proliferative diabetic retinopathy: outcomes from the RECOVERY randomized trial","author":"Wykoff","year":"2019","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"10.1016\/j.ajo.2019.10.012_bib24","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2307\/2309088","article-title":"The Cosine-Haversine formula","volume":"64","author":"Robusto","year":"1957","journal-title":"Am Math Mon"},{"key":"10.1016\/j.ajo.2019.10.012_bib26","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamaophthalmol.2018.1544","article-title":"Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration Chroma and Spectri phase 3 randomized clinical trials","volume":"136","author":"Holz","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajo.2019.10.012_bib28","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.jcjo.2017.09.025","article-title":"Analysis of reasons for noncompliance with laser treatment in patients of diabetic retinopathy","volume":"52","author":"Hua","year":"2017","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.ajo.2019.10.012_bib29","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","author":"Dugel","year":"2019","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2019.10.012_bib30","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase iii randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.ajo.2019.10.012_bib31","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","article-title":"Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies","volume":"123","author":"Heier","year":"2016","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2019.10.012_bib32","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3928\/23258160-20190129-06","article-title":"Analysis of patient-reported barriers to diabetic retinopathy follow-up","volume":"50","author":"Lu","year":"2019","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.ajo.2019.10.012_bib33","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.2147\/OPTH.S114006","article-title":"Comorbitiy and health care visit burden in working-age commercially insured patients with diabetic macular edema","volume":"10","author":"Kiss","year":"2016","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2019.10.012_bib34","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s11606-010-1253-9","article-title":"Primary medication non-adherence: analysis of 195,930 electronic prescriptions","volume":"25","author":"Fischer","year":"2010","journal-title":"J Gen Intern Med"},{"issue":"7","key":"10.1016\/j.ajo.2019.10.012_bib35","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2019.10.012_bib36","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ajo.2019.10.012_bib37","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.ophtha.2018.06.002","article-title":"Lessons from recent phase III trial failures: don't design phase III trials based on retrospective subgroup analyses from phase II trials","volume":"125","author":"Rosenfeld","year":"2018","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ajo.2019.10.012_bib38","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/NMD.0000000000000844","article-title":"Difficulties in conducting long term follow ups in psychotherapy research\u2014issues in the literature and data from a randomized therapy comparison study for posttraumatic stress disorder","volume":"206","author":"K\u00f6nig","year":"2018","journal-title":"J Nerv Ment Dis"},{"issue":"10","key":"10.1016\/j.ajo.2019.10.012_bib39","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.2105\/AJPH.84.10.1669","article-title":"Patient adherence to guidelines for diabetes eye care: results from the diabetic eye disease follow-up study","volume":"84","author":"Will","year":"1994","journal-title":"Am J Public Health"},{"issue":"5","key":"10.1016\/j.ajo.2019.10.012_bib40","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1046\/j.1365-2710.2001.00363.x","article-title":"Patient adherence to treatment: three decades of research. A comprehensive review","volume":"26","author":"Vermeire","year":"2001","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.ajo.2019.10.012_bib41","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2147\/PPA.S30613","article-title":"Non-adherence in type 2 diabetes: practical considerations for interpreting the literature","volume":"7","author":"Blackburn","year":"2013","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.ajo.2019.10.012_bib42","series-title":"Facilitating treatment adherence: a Practitioner\u2019s guidebook","author":"Meichenbaum","year":"1987"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939419305057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939419305057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:41:24Z","timestamp":1757598084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939419305057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":39,"alternative-id":["S0002939419305057"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2019.10.012","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Noncompliance in Prospective Retina Clinical Trials: Analysis of Factors Predicting Loss to Follow-up","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2019.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}